The efficacy of Pentacel is based on the immunogenicity of the individual antigens compared to separately administered vaccines. The poliovirus component (poliovirus types 1, 2 and 3) of this formulation of Pentacel is grown in Vero cells [see Description (11)]. The clinical study data in this section were accrued with a Pentacel formulation in which the poliovirus component was grown in MRC-5 cells. The poliovirus component of the two Pentacel formulations are analytically comparable. Serological correlates of protection exist for diphtheria, tetanus, poliomyelitis, and invasive disease due to H. influenzae type b [see Clinical Pharmacology (12.1)]. The efficacy against pertussis, for which there is no well established serological correlate of protection, was based, in part, on a comparison of pertussis immune responses following Pentacel in US children to responses following DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) manufactured by Sanofi Pasteur Limited) in an efficacy study conducted in Sweden (Sweden I Efficacy Trial). While Pentacel and DAPTACEL contain the same pertussis antigens, manufactured by the same process, Pentacel contains twice as much detoxified PT and four times as much FHA as DAPTACEL.
Immune responses to Pentacel were evaluated in four US studies: Studies 494-01, P3T06, 494-03, and M5A10. The vaccination schedules of Pentacel, Control vaccines, and concomitantly administered vaccines used in Studies 494-01, P3T06, and 494-03 are provided in Table 1 [see Clinical Trials Experience (6.1)]. In Study M5A10, participants were randomized to receive Pentacel or separately administered DAPTACEL, IPOL, and ActHIB at 2, 4, and 6 months of age. 7-valent pneumococcal conjugate (PCV7, Wyeth Pharmaceuticals Inc.) at 2, 4, and 6 months of age, and Hepatitis B vaccine (Merck and Co. or GlaxoSmithKline Biologicals) at 2 and 6 months of age, were administered concomitantly with Pentacel or Control vaccines.
The proportions of participants achieving diphtheria antitoxin seroprotective levels one month following three and four doses of Pentacel or DAPTACEL in Study P3T06 are provided in Table 3.
The proportions of participants achieving tetanus antitoxoid seroprotective levels one month following three and four doses of Pentacel or DAPTACEL in Study P3T06 are provided in Table 3.
|Pentacel||DAPTACEL + IPOL + ActHIB|
|Per Protocol Immunogenicity population.|
|Post-Dose 3||N = 331-345||N = 1,037-1,099|
|Diphtheria Antitoxin % ≥0.01 IU/mL * % ≥0.10 IU/mL †Tetanus Antitoxoid % ≥0.10 IU/mL †||100.0% 98.8% 99.7%||100.0% 98.5% 100.0%|
|Post-Dose 4||N = 341-352||N = 328-334|
|Diphtheria Antitoxin % ≥0.10 IU/mL * % ≥1.0 IU/mL †Tetanus Antitoxoid % ≥0.10 IU/mL * % ≥1.0 IU/mL †‡||100.0% 96.5% 100.0% 92.9%||100.0% 95.7% 100.0% 99.4%|
In a clinical pertussis vaccine efficacy study conducted in Sweden during 1992-1995 (Sweden I Efficacy Trial), 2,587 infants received DAPTACEL and 2,574 infants received a non-US licensed DT vaccine as placebo at 2, 4, and 6 months of age. (1) The mean length of follow-up was 2 years after the third dose of vaccine. The protective efficacy of DAPTACEL against pertussis after 3 doses of vaccine using the World Health Organization (WHO) case definition (≥21 consecutive days of paroxysmal cough with culture or serologic confirmation or epidemiologic link to a confirmed case) was 84.9% (95% confidence interval [CI] 80.1%, 88.6%). The protective efficacy of DAPTACEL against mild pertussis (≥1 day of cough with laboratory confirmation) was 77.9% (95% CI 72.6%, 82.2%). Protection against pertussis by DAPTACEL was sustained for the 2-year follow-up period.
Based on comparisons of the immune responses to DAPTACEL in US infants (Post-Dose 3) and Canadian children (Post-Dose 4) relative to infants who participated in the Sweden I Efficacy Trial, it was concluded that 4 doses of DAPTACEL were needed for primary immunization against pertussis in US children. (1)
In a serology bridging analysis, immune responses to FHA, PRN and FIM in a subset of infants who received three doses of DAPTACEL in the Sweden I Efficacy Trial were compared to the Post-Dose 3 and Post-Dose 4 responses in a subset of US children from Study 494-01 who received Pentacel (Table 4). Available stored sera from infants who received DAPTACEL in the Sweden I Efficacy Trial and sera from children who received PCV7 concomitantly with the first three doses of Pentacel in Study 494-01 (Table 1) were assayed in parallel. Data on levels of antibody to PT using an adequately specific assay were not available for this serology bridging analysis.
Geometric mean antibody concentrations (GMCs) and seroconversion rates for antibodies to FHA, PRN and FIM one month following Dose 3 of DAPTACEL in the subset of infants from the Sweden I Efficacy Trial and one month following Dose 3 and Dose 4 of Pentacel in a subset of infants from US Study 494-01 are presented in Table 4. Seroconversion was defined as 4-fold rise in antibody level (Post-Dose 3/Pre-Dose 1 or Post-Dose 4/Pre-Dose 1). For anti-FHA and anti-FIM, the non-inferiority criteria were met for seroconversion rates, and for anti-FHA, anti-PRN, and anti-FIM, the non-inferiority criteria were met for GMCs, following Dose 4 of Pentacel relative to Dose 3 of DAPTACEL. The non-inferiority criterion for anti-PRN seroconversion following Dose 4 of Pentacel relative to Dose 3 of DAPTACEL was not met [upper limit of 95% CI for difference in rate (DAPTACEL minus Pentacel) = 13.24%]. Whether the lower anti-PRN seroconversion rate following Dose 4 of Pentacel in US children relative to Dose 3 of DAPTACEL in Swedish infants correlates with diminished efficacy of Pentacel against pertussis is unknown.
|Post-Dose 3 DAPTACEL Sweden I Efficacy Trial N = 80||Post-Dose 3 Pentacel * US Study 494-01 N = 730-995||Post-Dose 4 Pentacel † US Study 494-01 N = 507-554|
|Analyzed sera were from subsets of the Per Protocol Immunogenicity populations in each study. Data on anti-PT levels using an adequately specific assay were not available.|
|Anti-FHA % achieving 4-fold rise ‡ GMC (EU/mL)||68.8 40.70||79.8 71.46||91.7§ 129.85§|
|Anti-PRN % achieving 4-fold rise ‡ GMC (EU/mL)||98.8 111.26||74.4 38.11||89.2¶ 90.82§|
|Anti-FIM % achieving 4-fold rise ‡ GMC (EU/mL)||86.3 339.31||86.5 265.02||91.5§ 506.57§|
In a separate study, Study P3T06, US infants were randomized to receive either Pentacel or DAPTACEL + IPOL + ActHIB at 2, 4, 6, and 15-16 months of age (Table 1). The pertussis immune responses (GMCs and seroconversion rates) one month following the third and fourth doses were compared between the two groups (Table 5). Seroconversion was defined as a 4-fold rise in antibody level (Post-Dose 3/Pre-Dose 1 or Post-Dose 4/Pre-Dose 1). Data on anti-PT responses obtained from an adequately specific assay were available on only a non-random subset of study participants. The subset of study participants was representative of all study participants with regard to Pre-Dose 1, Post-Dose 3 and Post-Dose 4 GMCs of antibodies to FHA, PRN and FIM. For each of the pertussis antigens, non-inferiority criteria were met for seroconversion rates and GMCs following Dose 3 of Pentacel relative to Dose 3 of DAPTACEL. Following Dose 4 of Pentacel relative to Dose 4 of DAPTACEL, non-inferiority criteria were met for all comparisons except for anti-PRN GMCs [upper limit of 90% CI for ratio of GMCs (DAPTACEL/Pentacel) = 2.25]. Whether the lower anti-PRN GMC following Dose 4 of Pentacel relative to Dose 4 of DAPTACEL in US children correlates with diminished efficacy of Pentacel against pertussis is unknown.
|Post-Dose 3 Pentacel||Post-Dose 3 DAPTACEL + IPOL + ActHIB||Post-Dose 4 Pentacel||Post-Dose 4 DAPTACEL + ActHIB|
|Per Protocol Immunogenicity population for anti-FHA, anti-PRN, and anti-FIM. Non-random subset of per Protocol Immunogenicity population for anti-PT. See text for further information on the subset evaluated.|
|N = 143||N = 481-485||N = 113||N = 127-12 8|
|Anti-PT % achieving 4-fold rise * GMC (EU/mL)||95.8† 102.62†||87.3 61.88||93.8‡ 107.89‡||91.3 100.29|
|N = 218-318||N = 714-1,016||N = 230-367||N = 237-347|
|Anti-FHA % achieving 4-fold rise * GMC (EU/mL)||81.9§ 73.68§||60.9 29.22||88.4¶ 107.94¶||79.3 64.02|
|Anti-PRN % achieving 4-fold rise * GMC (EU/mL)||74.2§ 36.05§||75.4 43.25||92.7¶ 93.59#||98.3 186.07|
|Anti-FIM % achieving 4-fold rise * GMC (EU/mL)||91.7§ 268.15§||86.3 267.18||93.5¶ 553.39¶||91.6 513.54|
VxLabels.com provides trustworthy package insert and label information about marketed drugs and vaccines as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VxLabels.com. Every individual vaccine label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.